LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Inicio・Lista de Acciones・Innoviva Inc

Innoviva Inc

Cerrado

SectorSanidad

22.45 1.35

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

21.82

Máximo

22.49

Métricas clave
By Trading Economics
Ingresos	-55M 187M
Ventas	-20M 98M
P/B Media del Sector	3.482 49.701
BPA	0.468
Margen de beneficios	190.415
Empleados	159
EBITDA	-160M 48M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+55.86% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-93M 1.6B
Apertura anterior	21.1
Cierre anterior	22.45

Noticias sobre sentimiento de mercado

By Acuity

19%

81%

27 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

18.57 / 18.75 Soporte y Resistencia

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 may 2026, 16:33 UTC

Ganancias

Principales Movimientos del Mercado

Webull Shares Slide on 1Q Loss, Soaring Costs

22 may 2026, 21:10 UTC

Ganancias

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2026, 19:47 UTC

Ganancias

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 may 2026, 19:17 UTC

Charlas de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 may 2026, 19:10 UTC

Charlas de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 may 2026, 18:38 UTC

Charlas de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 may 2026, 18:35 UTC

Adquisiciones, fusiones, absorciones

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 may 2026, 18:09 UTC

Charlas de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 may 2026, 17:58 UTC

Charlas de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 may 2026, 17:54 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

22 may 2026, 17:54 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 may 2026, 17:54 UTC

Charlas de Mercado

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 may 2026, 17:03 UTC

Charlas de Mercado

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 may 2026, 16:54 UTC

Charlas de Mercado

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2026, 16:16 UTC

Charlas de Mercado

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

22 may 2026, 15:55 UTC

Charlas de Mercado

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 may 2026, 15:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 may 2026, 15:42 UTC

Charlas de Mercado

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 may 2026, 15:35 UTC

Charlas de Mercado

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

55.86% repunte

Estimación a 12 Meses

Media 34.6 USD 55.86%

Máximo 46 USD

Mínimo 18 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

18.57 / 18.75Soporte y Resistencia

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

27 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.